In recent years, researchers have realized that many products, including pharmaceuticals, have ended up where they’re not supposed to be — in our drinking water. But now scientists have developed a way to make drugs that break down into harmless compounds before they contaminate our taps. Their report appears in ACS’ journal Environmental Science & Technology.
A wide range of active ingredients originating from pesticides, shampoos, lotions, cosmetics, disinfectants and drugs get washed into sewage systems or rivers and streams, ending up in our tap water. Scientists don’t have a complete picture yet of what effects these substances have on wildlife and human health, but they are a major concern. Researchers have detected them in low levels in streams and rivers across the United States and in other countries. To address the specific problem of medications in the environment, Klaus Kümmerer and colleagues made tweaks to pharmaceuticals so they degrade after they’ve passed through both the body and sewage treatment systems, which aren’t capable of scrubbing wastewater of all contaminants.
The researchers chose to work with a commonly used drug called propranolol — a beta blocker prescribed to treat high blood pressure and to prevent heart problems. It is very stable and has been found in sewage. They made a small molecular change in its structure that didn’t affect its beta blocking activity but allowed it to break down more easily than the original form. Further studies are needed, but initial testing showed that the altered drug and its byproducts are likely not toxic. The researchers suggest that a similar approach could be used to re-design other classes of drugs and chemicals to make them more environmentally friendly, too.
The Latest on: Pharmaceuticals that degrade
[google_news title=”” keyword=”Pharmaceuticals that degrade” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pharmaceuticals that degrade
- What EPA, researchers and cleaning industry say about detergent podson May 3, 2024 at 9:03 am
Polyvinyl alcohol, or PVA, is used in everything from detergent pods and pharmaceuticals to clothing and medical devices.
- CNS Pharmaceuticals Inc Ordinary Shares CNSPon May 3, 2024 at 6:00 am
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
- Oppenheimer Keeps Their Buy Rating on Kymera Therapeutics (KYMR)on May 2, 2024 at 11:08 pm
Jones covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Perspective Therapeutics, and Corbus Pharmaceuticals ... The company is advancing the field of targeted protein ...
- Governor Cheboi faces impeachment amid audit querieson May 2, 2024 at 5:11 am
Kiplagat alleges that there are rampant cases of degradation of the procurement and tendering ... Sh103 million as per the audit was incurred on the purchase of pharmaceuticals, non-pharmaceuticals, ...
- Salarius Pharmaceuticals Inc SLRXon April 30, 2024 at 5:00 pm
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
- Asia-Pacific Cold Chain Logistics Market 2024 Feasibility Analysis, Research Methodology, Major Trends, and Industry Outlook to 2032on April 29, 2024 at 9:32 pm
Pacific Cold Chain Logistics Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising due to strategies adopted by key players. The report ...
- Pharmaceuticals Newson April 26, 2024 at 8:24 am
Showcase your company news with guaranteed exposure both in print and online Small businesses are the foundation of our economy, facing unprecedented challenges. DBJ ...
- Intas Pharmaceuticals Gets CDSCO Panel Nod to Study Trastuzumab Emtansine in Metastatic Breast Canceron April 26, 2024 at 5:30 am
Trastuzumab emtansine binds to the HER2 receptor's sub-domain IV and goes into the cell by receptor-mediated endocytosis. Lysosomes degrade trastuzumab emtansine and release DM1. DM1 binds to tubulin ...
- Rebounding R&D returns spell success for local pharmaceutical companies, report showson April 26, 2024 at 2:33 am
Investments in drug research and development are paying dividends while the cost to do so stays flat, a trend that appears to be benefitting local firms.
- DOH warns doctors getting payoffs stand to lose licenseon April 23, 2024 at 10:00 am
The Department of Health (DOH) cautioned doctors on Tuesday that accepting “gifts” in exchange over their preferences of a company’s manufactured pharmaceuticals could cost them their licenses.
via Bing News